公开(公告)号：EP3630283A1

公开(公告)日：2020-04-08

申请号：EP18810795.7

申请日：2018-05-31

申请人： Immunolight, LLC ,  Duke University

发明人： BOURKE, Frederic A. ,  DEWHIRST, Mark ,  SPECTOR, Neil ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya ,  OLDHAM, Mark ,  FATHI, Zakaryae ,  BEYER, Wayne F. ,  WALDER, Harold

IPC分类号： A61N5/06 ,  A61B6/00 ,  A61K9/00 ,  A61K49/04 ,  A61N5/10

公开(公告)号：EP3365017A1

公开(公告)日：2018-08-29

申请号：EP16858126.2

申请日：2016-10-19

申请人： Immunolight, LLC ,  Duke University

发明人： FATHI, Zakaryae ,  BAYER, Wayne, F. ,  WALDER, Harold ,  BOURKE, Frederic, A. ,  OLDHAM, Mark ,  DEWHIRST, Mark ,  SPECTOR, Neil, L. ,  YOON, Paul ,  ADAMSON, Justus ,  ALCORTA, David ,  LYERLY, Kim ,  LIU, Leihua ,  OSADA, Takuya

IPC分类号： A61K41/00

CPC分类号： A61K41/0057 ,  A61K33/42 ,  A61K41/0066 ,  A61N5/00 ,  A61N5/062 ,  A61N5/10 ,  A61N2005/1098

摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：EP3166630A1

公开(公告)日：2017-05-17

申请号：EP15818810.2

申请日：2015-07-07

申请人： Duke University

发明人： LYERLY, Herbert K. ,  OSADA, Takuya ,  HARTMAN, Zachary C.

IPC分类号： A61K39/00 ,  C07K1/00 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K38/17 ,  A61K38/177 ,  A61K38/45 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/53 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/76 ,  C12N7/00 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12Y207/10001

摘要： Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.

摘要翻译： 本文提供了降低癌症或癌症前期对癌症治疗剂或预防剂产生抗性的可能性的方法。 所述方法包括向受试者施用癌症治疗剂或预防剂和包含编码多肽的多核苷酸的疫苗，所述多肽的表达或活化与癌症或癌前期对癌症治疗或预防剂的抗性的发展相关。 疫苗可以包括编码ESR1多肽或其截短，缺失或取代突变体的多核苷酸。 还提供了使用包含编码ESR1多肽的多核苷酸来治疗癌症或癌前期的疫苗的方法。

公开(公告)号：EP2804624B1

公开(公告)日：2018-12-26

申请号：EP13738296.6

申请日：2013-01-21

申请人： Duke University

发明人： LYERLY, Herbert, K. ,  MORSE, Michael, A. ,  OSADA, Takuya ,  CLAY, Timothy ,  HARTMAN, Zachary, C.

IPC分类号： A61K39/00 ,  A61K39/395

CPC分类号： A61K39/0011 ,  A61K31/517 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/585 ,  C07K16/32 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  A61K2300/00

摘要： Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polyepptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.

公开(公告)号：EP3166646A1

公开(公告)日：2017-05-17

申请号：EP15818471.3

申请日：2015-07-07

申请人： Duke University

发明人： LYERLY, Herbert K. ,  OSADA, Takuya ,  HARTMAN, Zachary C.

IPC分类号： A61K48/00 ,  C07H21/04 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K38/45 ,  A61K39/3955 ,  A61K2039/53 ,  C07H21/04 ,  C07K16/2818 ,  C07K2317/76 ,  C12N7/00 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12Y207/10001 ,  A61K2300/00

摘要： Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.

摘要翻译： 中是提供了一种减少癌症的可能性或初癌发展抗性的癌症治疗剂或预防的方法。 所述方法包括施用一种疫苗，其包含编码性的多肽，其表达或活化与所述癌症或癌症前期在癌症治疗剂或预防剂的耐药性的发展相关联的对象的多核苷酸。 疫苗可以包括编码HER2 poiypeptide或其截短，缺失或突变体subsiitiition的多核苷酸。 因此，提供使用所述疫苗包含编码所述多肽HER2治疗癌症或癌症前期的多核苷酸的方法。 疫苗可以与癌症治疗剂或预防剂或检查点抑制剂的免疫调节剂一起施用。

公开(公告)号：EP3096782A2

公开(公告)日：2016-11-30

申请号：EP15739848.8

申请日：2015-01-21

申请人： MedImmune, LLC ,  Duke University

发明人： HAMMOND, Scott A. ,  MORSE, Michael A. ,  OSADA, Takuya ,  LYERLY, Herbert Kim

IPC分类号： A61K39/00 ,  A61K39/395

CPC分类号： C07K16/3007 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/732

摘要： Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and T cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific T cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a T cell surface antigen.

摘要翻译： 本文提供了调节和重定向免疫应答的方法。 还提供了用于杀死细胞群体中的靶细胞的组合物和方法，其中将含有表达靶相关抗原和T细胞的靶细胞的细胞群与1,2或更多免疫检验点拮抗剂和多特异性T细胞重定向剂 其特异性结合目标细胞上表达的靶标相关抗原并特异性结合T细胞表面抗原。

公开(公告)号：EP2804624A2

公开(公告)日：2014-11-26

申请号：EP13738296.6

申请日：2013-01-21

申请人： Duke University

发明人： LYERLY, Herbert, K. ,  MORSE, Michael, A. ,  OSADA, Takuya ,  CLAY, Timothy ,  HARTMAN, Zachary, C.

IPC分类号： A61K39/00

CPC分类号： A61K39/0011 ,  A61K31/517 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/585 ,  C07K16/32 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  A61K2300/00

摘要： Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.

公开(公告)号：EP1994163A2

公开(公告)日：2008-11-26

申请号：EP07753369.3

申请日：2007-03-16

申请人： HEALTH RESEARCH, INC. ,  Duke University

发明人： FERRONE, Soldano ,  WANG, Xinhui ,  CLAY, Tim ,  LYERLY, Kim, H. ,  MORSE, Michael, A. ,  DEVI, Gay ,  OSADA, Takuya

IPC分类号： C12P19/00

CPC分类号： G01N33/57415 ,  A61K51/1051 ,  A61K51/1066 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/3053

摘要： Disclosed is a method for inhibiting the growth of breast carcinoma stem cells, that express High Molecular Weight-Melanoma Associated Antigen (HMW-MAA). The method comprises administering to an individual a composition comprising an antibody reactive with HMW-MAA or a fragment of such an antibody in an amount effective to inhibit the growth of the breast carcinoma cells. Also provided are methods for inhibiting metastasis of breast carcinomas and methods for identifying HMW-MAA+ breast cancer stem cells.